Evidence map›Paper›PMID 27491931›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016

Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy.

Mingzhen Zhang, Bo Xiao, Huan Wang, Moon Kwon Han, Zhan Zhang, Emilie Viennois, Changlong Xu, Didier Merlin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 240 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 3 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Natural Product-Derived Vesicles in Nanotherapeutics.Journal of extracellular vesicles · 2026
    Review
  8. Review
  9. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Mingzhen ZhangInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Bo XiaoInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Huan WangCenter for Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia, USA.
Moon Kwon HanInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Zhan ZhangInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Emilie ViennoisInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Changlong XuInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Didier MerlinInstitute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
Georgia State University · USSouthwest University · CN

Funding

ROLE OF CD98 IN INTESTINAL PERMEABILITYR01DK071594 · NIDDK · GEORGIA STATE UNIVERSITY · PI MERLIN, DIDIER · 2006 to 2017
$3.3M
Small intestinal PepT1 expression plays a critical role in maintaining intestinal homeostasis and in shaping the gut microbiotaI01BX002526 · VA · VETERANS HEALTH ADMINISTRATION · PI MERLIN, DIDIER · 2014 to 2024
–
BLRD VA I01 BX002526NIDDK NIH HHS R01 DK071594
6 · The paper itself

Abstract

The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large-scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe a nanovector made from ginger-derived lipids that can serve as a delivery platform for the therapeutic agent doxorubicin (Dox) to treat colon cancer. We created nanoparticles from ginger and reassembled their lipids into ginger-derived nanovectors (GDNVs). A subsequent characterization showed that GDNVs were efficiently taken up by colon cancer cells. Viability and apoptosis assays and electric cell-substrate impedance-sensing technology revealed that GDNVs exhibited excellent biocompatibility up to 200 μmol/l; by contrast, cationic liposomes at the same concentrations decreased cell proliferation and increased apoptosis. GDNVs were capable of loading Dox with high efficiency and showed a better pH-dependent drug-release profile than commercially available liposomal-Dox. Modified GDNVs conjugated with the targeting ligand folic acid mediated targeted delivery of Dox to Colon-26 tumors in vivo and enhanced the chemotherapeutic inhibition of tumor growth compared with free drug. Current experiments explore the feasibility of producing nature-derived nanoparticles that are effective as a treatment vehicle while potentially attenuating the issues related to traditional synthetic nanoparticles.

Indexed as

AnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalColonic NeoplasmsDoxorubicinDrug CarriersDrug Delivery SystemsHT29 CellsHumansLipidsMiceNanoparticlesXenograft Model Antitumor AssaysZingiber officinaleDoxorubicinDrug CarriersLipids

Identifiers

PMID27491931
PMCPMC5112046
OpenAlexW2486594993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.